Hoth Therapeutics Inc. (NASDAQ:HOTH) shares are up on Tuesday as the company reported positive data from its HT-VA study, which highlights the potential of GDNF as a next-generation therapy for metabolic-associated fatty liver disease (MAFLD).
Hoth Therapeutics Candidate Shows Impact On Fat Production And Metabolism
The HT-VA study demonstrated that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) significantly reduces fat production and enhances fat metabolism at the genetic level, positioning it as a unique therapeutic option for MAFLD and obesity.
Hoth Therapeutics is a clinical-stage biopharmaceutical company.
The data show statistically significant modulation of genes linked to hepatic fat dynamics, positioning GDNF as a differentiated approach targeting underlying drivers of fatty liver disease and metabolic dysfunction.
- Reduced Srebf1, a key regulator of hepatic fat production.
- Increased Pparα, a central driver of fat metabolism and oxidation
- Outperformed Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy or Ozempic) on key gene expression markers tied to liver fat regulation.
- Demonstrated broad metabolic effects at the genetic level beyond weight loss.
Strategic Implications For MAFLD And Obesity Markets
- Positions the company for entry into MAFLD/NASH and obesity markets
- Differentiates from GLP-1 therapies via a gene-level mechanism
- Supports potential for a first-in-class metabolic reprogramming approach
- Extends pipeline beyond core dermatology and oncology focus.
Next Steps In Development And Partnerships
- Advance into additional preclinical validation studies.
- Assess clinical development pathways in metabolic and liver diseases.
- Pursue partnerships to accelerate development and commercialization.
HOTH Stock Price Activity: Hoth Therapeutics shares were up 42.02% at $0.729 at the time of publication on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
Login to comment